Latest Contract Manufacturing News

6K Additive surged to a US$13.3 million half-year revenue, up 73% year-on-year, driven by strong demand in its Powder and Alloy segments. The company is on track to nearly quadruple production capacity by the end of 2026, supported by substantial US government funding and a new EXIM loan facility.

NeuroScientific Biopharmaceuticals posted a $4.69 million loss for FY2026, driven by R&D ramp-up and clinical progress with its StemSmart™ platform, while halting independent development of its glaucoma drug EmtinB to pursue licensing deals.

Entropy Neurodynamics has partnered with BioCina to establish GMP manufacturing for its intravenous psilocin formulation TRP-8803, a critical step toward late-stage clinical trials and commercialisation.

Wide Open Agriculture (ASX: WOA) has taken a significant step towards a capital-light production model by signing a non-binding framework agreement with Proeon Foods for contract manufacturing of its lupin-based ingredients, including exclusive Indian distribution rights.

Wellnex Life has agreed to sell its Pain Away brand to Mentholatum Australasia for up to A$21.3 million, aiming to wipe out debt and sharpen its strategic focus.

Structural Monitoring Systems Plc (ASX: SMN) reported a milestone FY26 with record revenue of $32.5 million and net profit rising to $1.2 million, driven by strong avionics growth and progressing FAA certification for its CVMTM smart sensor technology.

The Calmer Co. has signed a binding heads of agreement with Kaiming Agro Processing to establish a long-term manufacturing partnership, leveraging advanced extraction technology in Fiji to scale its premium botanical ingredients business globally.

Wide Open Agriculture (ASX: WOA) is executing a major strategic pivot by closing its German production site and transitioning to a capital-light contract manufacturing model to improve economics and scale lupin protein production.

Wide Open Agriculture is closing its German plant and pivoting to contract manufacturing in Asia to cut costs and scale lupin ingredient production efficiently under new CEO Craig Swan.

Lumos Diagnostics has received a A$709,837 cash refund from the Australian Government’s R&D Tax Incentive, bolstering its investment in proprietary point-of-care diagnostic technologies.

TruScreen Group posted a NZ$2.25 million loss for FY2026, with its auditor highlighting material uncertainty over the company’s ability to continue without further funding. Revenue rose to NZ$2.4 million amid geographic expansion, but cash burn and accumulated losses remain significant.

Island Pharmaceuticals has kicked off GMP manufacturing of its antiviral Galidesivir to support late-stage Marburg virus studies under the FDA Animal Rule, marking a key step towards regulatory submission and biodefence readiness.